1. Scrip
  2. >>Business

Intas' biosimilar Enbrel debuts at hefty discount in India

 
• By Anju Ghangurde

Intas Pharmaceuticals has launched its cut-price etanercept, a biosimilar version of Amgen's TNF-inhibitor Enbrel, on the Indian market.

Intas Pharmaceuticals has launched its cut-price etanercept, a biosimilar version of Amgen's TNF-inhibitor Enbrel, on the Indian market.

Intas' etanercept (marketed as Intacept), available in two strengths 25mg in 0.5ml and 50mg in 1.0ml preservative-free solution, joins Cipla's...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

 
• By Anju Ghangurde

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.